The company plans to call for co-development of this product with a marketing partner.
Mahesh Patel, president and CEO of Lipocine, said: “Our patented Lip’ral-SSR technology enabled this breakthrough for the ‘once-a-day’ formulation that will improve patient compliance in a meaningful way for schizophrenia and bipolar disorder sufferers.
“In addition, sustained release formulations enabled by Lipocine’s Lip’ral SSR technology offer the potential to improve therapy and side effect profile for drugs such as Ziprasidone.”